Atryn Articles
GTC Biothera agrees to go private for $0.30 a share
9 November 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Lundbeck launches ATryn in USA
7 May 2009
GTC pursuing legal action against LEO
23 March 2009
GTC Bio gains $1M ATryn milestone
16 March 2009
FDA panel gives nod to GTC's antithrombin
19 January 2009
GTC's 3rd-qtr net loss narrows to $6.1M
17 November 2008
FDA accepts Ovation's ATryn BLA filing
13 October 2008
FDA priority review for GTC's Atryn
15 September 2008
GTC completes BLA filing for ATryn
18 August 2008
GTC's ATryn granted orphan status by FDA
17 December 2007
FDA fast-track for GTC's ATryn
10 September 2007
ATryn introduced at ISTH conference
26 July 2007
MA for GTC Bio's ATryn goes to Leo
8 January 2007
GTC Bio restructures to support programs
9 February 2004
Showing 1-19 of 19 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
